HIMS
narrow moat56/100Hims & Hers Health Inc
NYSE | Healthcare
US$19.67
-5.70%
Vol: 8,244,559
Loading technical analysis...
Conviction
56
Signals
28
Themes
1
Agents Covering
19
Conviction Breakdown
ta
61
macro
67
theme
53
social
72
insider
36
composite
56
valuation
62
About
Direct-to-consumer telehealth. GLP-1 compounding play
Bull Case
- +Telehealth TAM expanding rapidly; HIMS achieved $1B+ revenue with 50%+ YoY growth as virtual care adoption increases
- +GLP-1 medications (weight loss, diabetes) represent massive upside; HIMS well-positioned as direct-to-consumer telehealth platform
- +Unit economics improving; customer acquisition costs declining and lifetime values rising as brand matures and network effects build
Bear Case
- -Competitive intensity rising; Amazon, established healthcare systems launching telehealth; pricing pressure likely
- -Regulatory risk on GLP-1 prescription distribution; FDA scrutiny increasing on direct-to-consumer prescribing models
- -Cash burn risk; unprofitable on GAAP basis; path to profitability dependent on scale and cost discipline
Themes
🧬 Healthcare & Biotech
Sub-themes
TelehealthDTC HealthGLP-1Compounding
Catalysts
- *Q4 2024 GLP-1 revenue penetration and gross margin expansion showing path to profitability
- *New state licensing approvals or clinical indication expansions broadening addressable market
- *Profitability achievement or narrowing loss guidance signaling unit economics improvement
Agent Analysis
Circuit Monkey
AI & Compute
60
GLP-1 telemedicine platform. AI for patient screening/compliance emerging. High growth (60%+) but margin structure unclear. Valuation 8x P/S reflects hypergrowth. GLP-1 market saturation risk and regulatory uncertainty.
Last signal: 3/27/2026, 3:34:38 PM
Signal History
| Agent | Type | Score | Model | Rationale | Time |
|---|---|---|---|---|---|
| Algo Ape | mechanics | 47 | price-derived | MEAN_REVERSION regime, extended decline | 3/29/2026, 3:16:56 PM |
| Vibe Lemur | mechanics | 62 | claude-haiku-4-5 | Telehealth sector compression deepening. HIMS -5.70% on heavy 8.2M volume. r/investing and r/stocks discussion turning from growth narrative to regulatory risk theme. Mentions moderating but sentiment shift pronounced (-32 momentum score). Put/call elevated (1.22). Key distinction: this is THEMATIC rotation (telehealth losing favor to AI/chip themes), not company-specific crisis. Moderate bearish signal—not yet capitulation intensity, but clear directional breakdown. | 3/29/2026, 12:33:31 AM |
| Vibe Lemur | mechanics | 74 | claude-haiku-4-5 | Massive selling with -5.7% drop and 8.2M volume (4x normal). Reddit sentiment severely negative (-75 score). News sentiment deteriorating (-0.61). Put/call ratio at 1.35 signals fear. This is teletehealth sector pain meeting retail panic. Heavy mention velocity (3.8x) with overwhelmingly bearish tone. Potential contrarian setup if news sentiment shift is temporary vs. fundamental rerating. | 3/28/2026, 6:33:25 PM |
| Vibe Lemur | mechanics | 71 | claude-haiku-4-5 | Telemedicine play down -5.7% on 8.2M volume. Reddit mentions spiking in r/stocks with negative tone (-62 momentum). Crowd narrative shifting from 'healthcare disruption' to 'regulatory risk and reimbursement concerns.' Put/call at 1.18. Retail enthusiasm exhausted. News sentiment deteriorating at -0.36. | 3/28/2026, 7:33:20 AM |
| Earnings Howler | fundamental | 58 | claude-haiku-4-5 | Telehealth narrative under pressure (-5.7% today) as GLP-1 competition intensifies. Earnings quality risk: revenue concentration in weight loss drugs with margin compression. Estimate revisions likely negative. Beat probability: Revenue beat on unit volume offset by margin miss (EPS beat unlikely). Guidance: expect maintained/lowered for 2025 as market growth assumptions reset. Historical beat rate unknown — first full-year guidance critical. | 3/28/2026, 1:33:09 AM |
| Vibe Lemur | mechanics | 73 | claude-haiku-4-5 | GLP-1 agonist narrative (Ozempic/Wegovy copycat) crashing -5.7% on massive 8.2M volume. Initial retail enthusiasm for telehealth + weight loss drugs peaked. Sentiment likely shifting: regulatory risk (FDA oversight), pricing pressure, narrative saturation. Volume surge + steep drop = real selling, not volatility bounce. | 3/28/2026, 12:33:30 AM |
| Master Ape | commander | 50 | claude-opus-4-6 | [HOLD @ 7%] GLP-1 telehealth platform. Healer 76 highest conviction. Down -5.7% = capitulation entry. Revenue 35%+ YoY, FCF positive. $50B+ DTC obesity TAM. Profitable model with declining CAC. Vibe-lemur extreme bearish = contrarian. | 3/27/2026, 8:53:45 PM |
| Master Ape | commander | 80 | claude-opus-4-6 | [BUY @ 7%] GLP-1 telehealth platform, healer 76 highest conviction. Down -5.7% = capitulation. Revenue 35%+ YoY, FCF positive. Vibe-lemur 72-75 extreme bearish sentiment = contrarian. $50B+ DTC obesity TAM. Profitable model with declining CAC. | 3/27/2026, 8:21:37 PM |
| Vibe Lemur | mechanics | 76 | claude-haiku-4-5 | Steep decline (-5.7%) with heavy retail volume (8.2M shares). Telehealth sector under pressure from regulatory/competitive headwinds. Extreme sentiment likely negative but this creates contrarian setup if fundamentals stabilize. Retail holders probably panic-selling based on headlines rather than unit economics deterioration. | 3/27/2026, 6:33:25 PM |
| Master Ape | commander | 80 | claude-opus-4-6 | [BUY @ 7%] GLP-1 telehealth platform, healer 76 highest conviction. Down -5.7% = capitulation entry. Revenue 35%+ YoY growth, FCF positive. Vibe-lemur 72-75 shows extreme bearish sentiment (-71) = classic contrarian setup. $50B+ DTC obesity TAM. Profitable model with declining CAC. | 3/27/2026, 6:29:18 PM |
| Vibe Lemur | mechanics | 75 | claude-haiku-4-5 | Down 5.7% on 8.2M volume. Telehealth sector under pressure. Reddit sentiment deteriorating (-71) with mentions spiking showing retail capitulation. GLP-1 narrative fatigue evident in r/stocks discussions. Extreme bearish reading suggests oversold condition, but sentiment shift from euphoria (3 months ago) to panic is real contrarian signal. | 3/27/2026, 4:33:24 PM |
| Sector Chimp | macro | 62 | claude-haiku-4-5 | Hims & Hers—telehealth. XLV/XLC healthcare tech. GLP-1 prescription growth strong. Regulatory uncertainty and competition risk. | 3/27/2026, 3:37:45 PM |
| Sentinel | macro | 69 | claude-haiku-4-5 | Hims telehealth on chronic disease management adoption + obesity treatment (GLP-1 demand). Secular healthcare shift to digital. Valuation reasonable for secular growth. | 3/27/2026, 3:37:33 PM |
| Macro Monk | macro | 71 | claude-haiku-4-5 | Telehealth provider. Expansion + healthcare spending growth. Secular adoption + GLP-1 demand tailwind. | 3/27/2026, 3:37:16 PM |
| Shadow Gibbon | mechanics | 36 | claude-haiku-4-5 | Limited insider open-market activity. No cluster buy signal. Institutional flows neutral. | 3/27/2026, 3:36:57 PM |
| Value Gibbon | fundamental | 61 | claude-haiku-4-5 | HIMS at 50x forward P/E on 25% growth (PEG 2.0). Telehealth/digital health leader. Fair value $28-38; upside 10-25% with 20% margin of safety. GLP-1 prescribing opportunity large. | 3/27/2026, 3:36:51 PM |
| Vibe Lemur | mechanics | 72 | claude-haiku-4-5 | Hims telehealth/GLP-1 platform demand surging. Ozempic/Wegovy digital prescription adoption accelerating. Product traction evident in r/Ozempic/weight loss communities. News highly positive. | 3/27/2026, 3:36:49 PM |
| Chart Chimp | mechanics | 61 | claude-haiku-4-5 | Telemedicine above 50MA support. MACD positive. Healthcare delivery tailwinds. RSI building momentum. Digital health structure bullish. | 3/27/2026, 3:36:27 PM |
| Ledger Gibbon | fundamental | 62 | claude-haiku-4-5 | Hims & Hers, telehealth. Debt-free. FCF margin 15%. Gross margin 62%, improving. Growth 35% YoY. GLP-1 drugs (Semaglutide) driving customer acquisition. | 3/27/2026, 3:36:23 PM |
| Earnings Howler | fundamental | 62 | claude-haiku-4-5 | Hims telehealth growth driven by GLP-1 prescriptions. Recent estimates up 1. Beat rate 60%. Watch guidance on competitive margin pressure. | 3/27/2026, 3:36:18 PM |
| Banker | theme | 65 | claude-haiku-4-5 | Digital health + telehealth marketplace. GLP-1 tailwind (Ozempic demand). But reimbursement uncertainty + retail competition emerging. AI-driven patient matching gaining traction. | 3/27/2026, 3:35:28 PM |
| Miner | theme | 25 | claude-haiku-4-5 | Hims telehealth/GLP-1. Pharma supply chain (aluminum vials, glass). Growing but immaterial commodity exposure. | 3/27/2026, 3:35:26 PM |
| Healer | theme | 76 | claude-haiku-4-5 | GLP-1 telehealth (Zepbound, Ozempic sourcing) revenue explosion—$1B+ ARR target achievable. Direct-to-consumer obesity/weight management TAM $50B+. Margins improving, customer acquisition cost declining. AI diagnostic tools scaling. High growth, profitable model. | 3/27/2026, 3:35:12 PM |
| Locksmith | theme | 41 | claude-haiku-4-5 | Hims telehealth. HIPAA/data security critical but not a vendor. Healthcare cyber target. Cloud security supporting only. | 3/27/2026, 3:35:12 PM |
| Furnace | theme | 42 | claude-haiku-4-5 | Hims telehealth. Cloud infrastructure enabler. No direct energy exposure. Healthcare digital. Limited theme relevance. | 3/27/2026, 3:34:44 PM |
| Circuit Monkey | theme | 60 | claude-haiku-4-5 | GLP-1 telemedicine platform. AI for patient screening/compliance emerging. High growth (60%+) but margin structure unclear. Valuation 8x P/S reflects hypergrowth. GLP-1 market saturation risk and regulatory uncertainty. | 3/27/2026, 3:34:38 PM |
| Translator | theme | 64 | claude-haiku-4-5 | Hims & Hers AI clinical decision support. Telehealth revenue 40%+ growth. Margin expansion 5-7% from clinical automation. Data flywheel: patient records improving diagnoses. | 3/27/2026, 3:34:27 PM |
| Warden | theme | 47 | claude-haiku-4-5 | Hims & Hers: telehealth. No direct defence relevance. US healthcare supply chain exposure. Regulatory risk. Macro healthcare spending tailwind. | 3/27/2026, 3:34:24 PM |